PL4243828T3 - Sposoby i kompozycje zawierające inhibitor KRasG12C i inhibitor VEGF do leczenia nowotworów litych - Google Patents

Sposoby i kompozycje zawierające inhibitor KRasG12C i inhibitor VEGF do leczenia nowotworów litych

Info

Publication number
PL4243828T3
PL4243828T3 PL21835890.1T PL21835890T PL4243828T3 PL 4243828 T3 PL4243828 T3 PL 4243828T3 PL 21835890 T PL21835890 T PL 21835890T PL 4243828 T3 PL4243828 T3 PL 4243828T3
Authority
PL
Poland
Prior art keywords
inhibitor
compositions
methods
solid tumors
krasg12c
Prior art date
Application number
PL21835890.1T
Other languages
English (en)
Inventor
Marie Evangelista
Mark Andrew MERCHANT
Jennifer Lee SCHUTZMAN
Ting-Kun Mark LIN
Stephanie Royer JOO
Sandhya Vinayak MANDLEKAR
Stuart G. LUTZKER
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of PL4243828T3 publication Critical patent/PL4243828T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL21835890.1T 2020-11-13 2021-11-11 Sposoby i kompozycje zawierające inhibitor KRasG12C i inhibitor VEGF do leczenia nowotworów litych PL4243828T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063113609P 2020-11-13 2020-11-13
PCT/US2021/058877 WO2022103905A1 (en) 2020-11-13 2021-11-11 Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors

Publications (1)

Publication Number Publication Date
PL4243828T3 true PL4243828T3 (pl) 2025-06-23

Family

ID=79185775

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21835890.1T PL4243828T3 (pl) 2020-11-13 2021-11-11 Sposoby i kompozycje zawierające inhibitor KRasG12C i inhibitor VEGF do leczenia nowotworów litych

Country Status (13)

Country Link
US (2) US12016862B2 (pl)
EP (1) EP4243828B1 (pl)
JP (2) JP2023550028A (pl)
KR (1) KR102975432B1 (pl)
CN (1) CN116568326A (pl)
AU (2) AU2021377810B2 (pl)
CA (1) CA3201521A1 (pl)
ES (1) ES3032036T3 (pl)
IL (1) IL301293A (pl)
MX (1) MX2023005529A (pl)
PL (1) PL4243828T3 (pl)
TW (2) TW202535399A (pl)
WO (1) WO2022103905A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102975432B1 (ko) * 2020-11-13 2026-06-10 제넨테크, 인크. 고형 종양 치료를 위한 krasg12c 억제제 및 vegf 억제제를 포함하는 방법 및 조성물
PL4504202T3 (pl) 2022-04-06 2026-05-04 Genentech Inc. Terapie skojarzone do leczenia raka obejmujące GDC-6036 i GDC-0077
CN116445411A (zh) * 2023-02-01 2023-07-18 复旦大学附属华山医院 一种小鼠结肠癌索托拉西布耐药细胞株及制备方法与应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
KR100335584B1 (ko) 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
CN104231078A (zh) 1997-04-07 2014-12-24 基因技术股份有限公司 抗-血管内皮生长因子的抗体
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
WO2014009319A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Indolinone derivatives anticancer compounds
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
UA127968C2 (uk) * 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
CA3090748A1 (en) * 2018-02-12 2019-08-15 Array Biopharma Inc. Methods and combination therapy to treat biliary tract cancer
WO2020097537A2 (en) * 2018-11-09 2020-05-14 Genentech, Inc. Fused ring compounds
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
KR102975432B1 (ko) * 2020-11-13 2026-06-10 제넨테크, 인크. 고형 종양 치료를 위한 krasg12c 억제제 및 vegf 억제제를 포함하는 방법 및 조성물

Also Published As

Publication number Publication date
US12409178B2 (en) 2025-09-09
JP2026082807A (ja) 2026-05-19
KR20230088781A (ko) 2023-06-20
US20240299392A1 (en) 2024-09-12
TW202535399A (zh) 2025-09-16
WO2022103905A1 (en) 2022-05-19
TWI886356B (zh) 2025-06-11
EP4243828A1 (en) 2023-09-20
CA3201521A1 (en) 2022-05-19
AU2021377810A1 (en) 2023-05-11
ES3032036T3 (en) 2025-07-15
TW202224682A (zh) 2022-07-01
EP4243828B1 (en) 2025-04-02
JP2023550028A (ja) 2023-11-30
US20220152030A1 (en) 2022-05-19
MX2023005529A (es) 2023-05-25
CN116568326A (zh) 2023-08-08
KR102975432B1 (ko) 2026-06-10
IL301293A (en) 2023-05-01
US12016862B2 (en) 2024-06-25
AU2021377810B2 (en) 2025-01-02
AU2025201610A1 (en) 2025-03-27

Similar Documents

Publication Publication Date Title
IL272877A (en) SHP2 inhibitory compositions and methods for cancer treatment
PT4181920T (pt) Inibidor de kat6 e combinações para o tratamento do cancro da mama
IL277783A (en) SHP2 inhibitory compositions, methods for treating cancer and methods for identifying a subject with SHP2 mutations
IL286350A (en) Preparations and methods for the treatment of cancer
ZA202006627B (en) Methods and compositions for treating cancer
IL288914A (en) Preparations and methods for the treatment of cancer
ZA202104870B (en) Methods and compositions for treating cancer
IL285886A (en) Preparations and methods for the treatment of laminopathy
EP4025590A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
IL285796A (en) Methods and preparations for the treatment of cancer
SG11202012435UA (en) Compositions and methods for treating cancer
IL287982A (en) Preparations and methods for the treatment of cancer
SG11202010089QA (en) Compositions and methods for treatment of iron overload
IL287865A (en) Pde9 inhibitors for treating thalassemia
IL315800A (en) Preparations and methods for the treatment of cancer
IL286153A (en) Methods and preparations for the treatment of cancer
SG11202104692VA (en) Compositions and methods for treating cancer
IL309120A (en) Methods and compositions for the treatment of cancer
IL309071A (en) Methods and compositions for the treatment of cancer
SG11202010911WA (en) Methods and compositions for treating chronic urticaria
EP4069253A4 (en) METHOD AND COMPOSITIONS FOR TREATING GLIOBLASTOMA
IL319403A (en) Compositions and methods for treating advanced solid tumors
IL312846A (en) Methods and preparations for the treatment of cancer
IL285036A (en) Methods and preparations for the treatment of cancer
KR102479523B9 (ko) Cotl1 억제제를 유효성분으로 포함하는 비만 예방 또는 치료용 조성물